



ATHENS GREECE

28-29 SEPTEMBER 2018

Co-Chairs Matthias Preusser, AT Michael Weller, CH

ESMO PRECEPTORSHIP PROGRAMME **BRAIN TUMOURS**

Multidisciplinary management, standards of care, therapeutic targets and future perspectives

Athens, Greece 28-29 September 2018

CO-CHAIRS: Matthias Preusser, Austria **SPEAKERS:**

Michael Weller, Switzerland

Wolfgang Wick, Germany

Martin van den Bent, Netherlands Roland Goldbrunner, Germany Emilie Le Rhun, France

LEARNING OBJECTIVES

- To learn about the evidence base for diagnostic imaging, molecular pathology and neurocognitive assessment in brain tumor patients
- To understand the basis of multi-modality treatment of lower and higher-grade gliomas
- To learn about local and systemic treatment options for meningiomas
- To learn about the multi-modality management of brain metastasis patients including targeted therapies in patients with actionable driver mutations and with novel immunotherapies
- To learn about future developments in the management of gliomas, meningiomas, brain metastases and leptomeningeal carcinomatosis

ACCREDITATION

The programme of this event has been accredited with 8 ESMO-MORA category 1 points.

Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update his/her knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For future details, please refer to esmo.org.

ORGANIZATION and CONTACTS

ESMO Head Office **Education Department** Via Ginevra, 4 6900 Lugano Switzerland Email: courses@esmo.org

www.esmo.org



Friday, 28 September 2018

09:00-09:15 15'	Opening and welcome	
15'	Welcome and introduction	Michael Weller, CH
09:15-10:30 75'	Session 1 Diagnostic challenges of brain tumors	Chair: Matthias Preusser, AT
25'	Imaging	Martin van den Bent, NL
25'	Molecular pathology	Michael Weller, CH
25'	Neurocognitive assessment and patient-reported outcomes	Martin van den Bent, NL
10:30-11:00	Coffee break	
11:00-12:20 80'	Session 2 Glioblastoma	Chair: Michael Weller, CH
2x10'	2 x Participants clinical case discussion	Faculty
25'	Standards of care	Michael Weller, CH
25'	Future developments	Michael Weller, CH
10'	Discussion	Faculty
12:20-13:20	Lunch	
13:20-14:40 80'	Session 3 Lower grade glioma	Chair: Matthias Preusser, AT
2x10'	2 x Participants clinical case discussion	Faculty
25'	Standards of care	Roland Goldbrunner, DE
25'	Future developments	Martin van den Bent, NL
10'	Discussion	Faculty
14.40 15.10		
14:40-15:10	Coffee break	
15:10-16:30 80°	Coffee break Session 4 Meningioma	Chair: Michael Weller, CH
15:10-16:30	Session 4	
15:10-16:30 80'	Session 4 Meningioma	Michael Weller, CH
15:10-16:30 80' 2x10'	Session 4 Meningioma 2 x Participants clinical case discussion	Michael Weller, CH Faculty
15:10-16:30 80' 2x10' 25'	Session 4 Meningioma 2 x Participants clinical case discussion Standards of care	Michael Weller, CH Faculty Roland Goldbrunner, DE

Saturday, 29 September 2018

09:00-10:20 80'	Session 5 Brain metastasis	Chair: Matthias Preusser, AT
2x10'	2 x Participants clinical case discussion	Faculty
25'	Standards of care	Matthias Preusser, AT
25'	Future developments	Emilie Le Rhun, FR
10'	Discussion	Faculty

10:20-10:50	Coffee break	
10:50-12:10 80'	Session 6 Leptomeningial Carcinomatosis	Chair: Michael Weller, CH
2x10'	2 x Participants clinical case discussion	Faculty
25'	Standards of care	Emilie Le Rhun, FR
25'	Future developments	Matthias Preusser, AT
10'	Discussion	Faculty
12:10-12:25 15'	Closing remarks and farewell	Co-Chairs: Matthias Preusser, AT Michael Weller, CH
12:25-13:25	Lunch	

 $\textbf{Note} : \textit{Each 10 minute slot for clinical case discussion includes 5' case presentation and 5' Q\&A/panel discussion and 5' Q\&A/panel disc$

esmo.org